Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia

Published:2024-01 Issue: Volume:142 Page:106950
ISSN:0045-2068
Container-title:Bioorganic Chemistry
language:en
Short-container-title:Bioorganic Chemistry

Author:

Xiang Qiuping,Wu Tianbang,Zhang Cheng,Wang Chao,Xu Hongrui,Hu Qingqing,Hu Jiankang,Luo Guolong,Zhuang Xiaoxi,Wu Xishan,Zhang Yan,Xu Yong

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Molecular Biology,Biochemistry

Reference40 articles.

1. Acute myeloid leukemia;Dohner;N. Engl. J. Med.,2015

2. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002;Yamamoto;Cancer Causes Control,2008

3. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel;Dohner;Blood,2017

4. CREB-binding protein and p300: molecular integrators of hematopoietic transcription;Blobel;Blood,2000

5. Protein lysine acetylation by p300/CBP;Dancy;Chem. Rev.,2015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia;Journal of Medicinal Chemistry;2024-06-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP